

Tove Kirkegaard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10418180/publications.pdf>

Version: 2024-02-01

12
papers

1,014
citations

840776

11
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

1475
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | AKT activation predicts outcome in breast cancer patients treated with tamoxifen. Journal of Pathology, 2005, 207, 139-146. | 4.5 | 250 |
| 2 | Plasminogen Activator Inhibitor-1 Represses Integrin- and Vitronectin-Mediated Cell Migration Independently of Its Function as an Inhibitor of Plasminogen Activation. Experimental Cell Research, 1997, 232, 420-429. | 2.6 | 221 |
| 3 | A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone, 2004, 35, 1107-1119. | 2.9 | 131 |
| 4 | Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor-Positive Tumors of Tamoxifen-Treated Breast Cancer Patients. Clinical Cancer Research, 2007, 13, 1405-1411. | 7.0 | 105 |
| 5 | Matrix metalloproteinase-12 (MMP-12) in osteoclasts: new lesson on the involvement of MMPs in bone resorption. Bone, 2004, 34, 37-47. | 2.9 | 87 |
| 6 | High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor-Positive Metastatic Breast Cancer. Clinical Cancer Research, 2016, 22, 5514-5526. | 7.0 | 57 |
| 7 | Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Research and Treatment, 2007, 102, 173-179. | 2.5 | 41 |
| 8 | Molecular alterations in <i>AKT1</i> , <i>AKT2</i> and <i>AKT3</i> detected in breast and prostatic cancer by FISH. Histopathology, 2010, 56, 203-211. | 2.9 | 41 |
| 9 | Kinetic analysis of integrin-dependent cell adhesion on vitronectin. The inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides. FEBS Journal, 1998, 253, 669-674. | 0.2 | 36 |
| 10 | T47D breast cancer cells switch from ER/HER to HER/c-Src signaling upon acquiring resistance to the antiestrogen fulvestrant. Cancer Letters, 2014, 344, 90-100. | 7.2 | 23 |
| 11 | Engineering of conformations of plasminogen activator inhibitor-1. A crucial role of beta-strand 5A residues in the transition of active form to latent and substrate forms. FEBS Journal, 1999, 263, 577-586. | 0.2 | 13 |
| 12 | Expression of Tumor Necrosis Factor- α Converting Enzyme in Endocrine Cancers. American Journal of Clinical Pathology, 2008, 129, 735-743. | 0.7 | 9 |